专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

WO2022159533A1 METHODS OF TREATING FUCHS ENDOTHELIAL CORNEAL DYSTROPHY AFTER DESCEMETORHEXIS 审中-公开
公开(公告)号：WO2022159533A1
公开(公告)日：2022-07-28
申请号：PCT/US2022/013045
申请日：2022-01-20
申请人： KOWA COMPANY, LTD. , GORDON, Gary
发明人： SUEHIRA, Kazuhito
IPC分类号： A61K9/00 , A61K9/08 , A61K31/03 , A61K31/18 , A61K31/473 , A61K31/551
摘要： Methods for treating Fuchs endothelial corneal dystrophy ("FECD"), and medications that promote healing in FECD patients following descemetorhexis.

3. 发明申请

WO2016126115A2 PHARMACEUTICAL COMPOSITION COMPRISING PITAVASTATIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND VALSARTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 审中-公开
标题翻译：含有四肽或其药用盐的药物组合物，以及缬沙坦或药物可接受的盐
公开(公告)号：WO2016126115A2
公开(公告)日：2016-08-11
申请号：PCT/KR2016/001212
申请日：2016-02-04
申请人： JW PHARMACEUTICAL CORPORATION , KOWA COMPANY, LTD.
发明人： CHOI, Min-Seok , UM, Yun-Sik
IPC分类号： A61K31/47 , A61K31/41
CPC分类号： A61K31/41 , A61K9/2077 , A61K31/47 , A61K2300/00
摘要： Disclosed is a composite composition comprising pitavastatin or a pharmaceutically acceptable salt thereof, and valsartan or a pharmaceutically acceptable salt thereof and the composite pharmaceutical composition is more stable than simple formulations in combination, and is economically beneficial compared to a controlled-release formulation.
摘要翻译：公开了一种复合组合物，其包含匹伐他汀或其药学上可接受的盐和缬沙坦或其药学上可接受的盐，并且该复合药物组合物比单纯的制剂组合更稳定，并且与控释制剂。

4. 发明申请

WO1994005629A1 AZOXY COMPOUND 审中-公开
标题翻译： AZOXY化合物
公开(公告)号：WO1994005629A1
公开(公告)日：1994-03-17
申请号：PCT/JP1993001295
申请日：1993-09-10
申请人： KOWA COMPANY, LTD. , DEUSHI, Takeo , TAKAHASHI, Yoshio , ISHIWATA, Hiroyuki , OKUNO, Yukihiro , ODA, Toshiaki , SHIRATSUCHI, Masami , YAMAMOTO, Katsuhiro
发明人： KOWA COMPANY, LTD.
IPC分类号： C07C291/08
CPC分类号： C07C291/08 , A01N51/00
摘要： An azoxy compound represented by general formula (I), which has an excellent fungicidal activity against fungi which infect warm-blooded animals, agrohorticultural crops or fruits, thus being useful as medicine, veterinary drug and agrohorticultural fungicide. In formula (I), R1 represents hydrogen, halogen, hydroxy, lower alkoxy, lower alkoxy-lower alkoxy or X1-C=C-CH2O-, wherein X1 represents hydrogen or halogen; R2 represents hydrogen or lower alkyl; R3 represents hydrogen or lower alkyl; R4 represents hydrogen or X2-C=C-CH2O-, wherein X2 represents hydrogen or halogen; R5 represents hydrogen or lower alkyl; and n represents 0 or 1.
摘要翻译：由通式（I）表示的氧化偶氮化合物，其对感染温血动物，农业农作物或水果的真菌具有优异的杀真菌活性，因此可用作药物，兽药和农业园艺杀真菌剂。在式（I）中，R 1表示氢，卤素，羟基，低级烷氧基，低级烷氧基 - 低级烷氧基或X 1 -C = C-CH 2 O-，其中X 1表示氢或卤素; R2代表氢或低级烷基; R3代表氢或低级烷基; R4表示氢或X2-C = C-CH2O-，其中X2表示氢或卤素; R5代表氢或低级烷基; 并且n表示0或1。

5. 发明申请

WO2020175636A1 EXTRACELLULAR MATRIX MODULATING AGENT 审中-公开
公开(公告)号：WO2020175636A1
公开(公告)日：2020-09-03
申请号：PCT/JP2020/008101
申请日：2020-02-27
申请人： KRUSE, Friedrich E. , SCHLOTZER-SCHREHARDT, Ursula , KOWA COMPANY, LTD.
发明人： KRUSE, Friedrich E. , SCHLOTZER-SCHREHARDT, Ursula
IPC分类号： A61P27/02 , A61P43/00 , A61K31/55
摘要： The present invention provide an agent for modulating expression of extracellular matrix by corneal endothelial cells. The present invention pertains to an agent for modulating expression of extracellular matrix by corneal endothelial cells containing, 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof.

6. 发明申请

WO2019126597A1 METHODS OF TREATMENT OF HYPERTRIGL YCERIDEMIA 审中-公开
公开(公告)号：WO2019126597A1
公开(公告)日：2019-06-27
申请号：PCT/US2018/066976
申请日：2018-12-20
申请人： KOWA COMPANY, LTD. , GORDON, Gary
发明人： GORDON, Gary , OSHIMA, Ryu , SUEHIRA, Kazuhito
IPC分类号： A61K31/423 , A61P1/16 , A61P31/06
摘要： The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.

7. 发明申请

WO2013175661A1 APPARATUS AND METHOD FOR MEASURING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN 审中-公开
标题翻译：用于测量生物原始生理活性物质的装置和方法
公开(公告)号：WO2013175661A1
公开(公告)日：2013-11-28
申请号：PCT/JP2012/080253
申请日：2012-11-15
申请人： KOWA COMPANY, LTD.
发明人： HIRONO, Taisuke
IPC分类号： G01N21/51 , G01N21/82 , G01N21/03
CPC分类号： G01N21/49 , G01N21/0332 , G01N21/51 , G01N21/82 , G01N33/487 , G01N2021/0357 , G01N2021/0367 , G01N2021/4707 , G01N2201/064
摘要： With regard to the detection of a physiological active substance of biological origin and the measurement of its concentration in a sample, the invention provides a technique for moving gel particles that are produced in the sample without using a mechanical stirring member, and allows a highly accurate detection of the physiological active substance of biological origin and measurement of its concentration with a simple arrangement. By partial heating/cooling of a sample cell, thermal convection is generated within a mixture liquid in the sample cell, and as a result the gel particles that are produced in the mixture liquid are moved. In addition, based on the intensity of forward scattered light, the rate of change in the number of gel particles is measured.
摘要翻译：关于生物来源的生物活性物质的检测及其在样品中的浓度的测定，本发明提供一种移动在样品中生产的凝胶颗粒而不使用机械搅拌构件的技术，并且允许高精度检测生物来源的生理活性物质，并用简单的排列测定其浓度。通过对样品池进行部分加热/冷却，在样品池内的混合液体内产生热对流，结果，在混合液中产生的凝胶粒子移动。此外，基于前向散射光的强度，测定凝胶粒子数量的变化率。

8. 发明申请

WO2004028566A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF KIDNEY DISEASES 审中-公开
标题翻译：用于预防和治疗KIDNEY疾病的药物组合物
公开(公告)号：WO2004028566A1
公开(公告)日：2004-04-08
申请号：PCT/JP2003/012472
申请日：2003-09-30
申请人： KOWA COMPANY, LTD.
发明人： NAKAGAWA, Takashi , ISHIWATA, Hiroyuki , TAKIZAWA, Toshiaki , KANKE, Toru , WADA, Yasushi , KAWAGOE, Junichi
IPC分类号： A61K45/00
CPC分类号： A61K38/4846 , A61K38/08 , A61K38/482 , A61K38/4826 , G01N33/6893 , G01N2500/00 , G01N2800/347
摘要： The present invention relates to a pharmaceutical composition for prevention and treatment of kidney diseases comprising one or more effective component(s) of an activator for PAR-2 which is able to activate PAR-2 and a pharmaceutically acceptable carrier. The present invention further relates to a method for prevention and treatment of kidney diseases comprising administration of a pharmaceutical composition for prevention and treatment of kidney diseases containing an activator for PAR-2 which is able to activate PAR-2 to patients suffering from kidney diseases, and also relates to the use of an activator for PAR-2 which is able to activate PAR-2 for the manufacture of a pharmaceutical composition for prevention and treatment of kidney diseases. The present invention furthermore relates to a method for screening an effective ingredient for prevention and treatment of kidney diseases comprising screening of the activating action of the test substance to PAR-2.
摘要翻译：本发明涉及一种用于预防和治疗肾脏疾病的药物组合物，其包含一种或多种能够激活PAR-2的活化剂的有效成分和能够激活PAR-2和药学上可接受的载体。本发明还涉及一种用于预防和治疗肾脏疾病的方法，包括给予含有PAR-2活化剂的肾脏疾病的预防和治疗药物组合物，所述活化剂能够对患有肾脏疾病的患者激活PAR-2，并且还涉及能够激活PAR-2用于制备用于预防和治疗肾脏疾病的药物组合物的PAR-2的活化剂的用途。本发明还涉及筛选用于预防和治疗肾脏疾病的有效成分的方法，其包括将检测物质的活化作用筛选至PAR-2。

9. 发明申请

WO1990007506A1 PRODUCTION OF GLYCIDYL ETHER 审中-公开
标题翻译：生产甘油醚
公开(公告)号：WO1990007506A1
公开(公告)日：1990-07-12
申请号：PCT/JP1989001293
申请日：1989-12-25
申请人： KOWA COMPANY, LTD. , KAWAMURA, Kiyoshi , OTA, Tomio
发明人： KOWA COMPANY, LTD.
IPC分类号： C07D301/28
CPC分类号： C07D303/22 , C07D407/12
摘要： This invention relates to a method for producing a glycidyl ether of general formula (I), wherein A is an optionally substituted aryl or heteroaryl group and the asterisked carbon atom represents an asymmetric carbon atom, comprising reacting an aryl alcohol of the general formula A-OH, wherein A is as defined above, with an epihalohydrin in the presence of a quaternary ammonium salt and, if necessary, treating the reaction product with a base. This method can afford the glycidyl ether of formula (I), which is useful as an intermediate of drugs, especially a β-blocker, in a simplified manner with a high optical purity.

10. 发明申请

WO2022249071A1 PEMAFIBRATE AND/OR TOFOGLIFLOZIN FOR USE IN TREATING LIVER DISEASE 审中-公开
公开(公告)号：WO2022249071A1
公开(公告)日：2022-12-01
申请号：PCT/IB2022/054867
申请日：2022-05-25
申请人： KOWA COMPANY, LTD
发明人： KANETA, Noboru , OSHIMA, Ryu , PENDSE, Shona Sanchita , TANIGAWA, Ryohei
IPC分类号： A61K31/423 , A61K31/7048 , A61P1/16
摘要： Pemafibrate, tofogliflozin, or combinations thereof for use in treating human patients with liver diseases, particularly NASH patients suffering from liver stiffness or liver fibrosis, NASH patients with lobular inflammation, NASH patients with elevated LDL-C, and NASH patients with healthy triglyceride levels.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式